Byondis Business Reply

With this form you are requesting access to the most current, accurate and evidence-based educational, clinical, and scientific information about (investigational) agents being developed by Byondis. The information provided in response to unsolicited requests is not intended to be promotional or provide medical advice. Furthermore, information about (investigational) pipeline products provided in response to unsolicited requests does not imply approval by the Food and Drug Administration (FDA), European Medicines Agency (EMA) or other regulatory agencies for use of these products, nor does it establish the safety or efficacy of these products or uses. Furthermore, there is no guarantee that (investigational) pipeline products will receive approval from the Food and Drug Administration (FDA), European Medicines Agency (EMA) or other regulatory agencies. By submitting this form, you are consenting to receive marketing emails from Sunvalley Communication, publishers of ADC Review and Onco'Zine, 4960 S. Gilbert Road, Suite 1-286, Chandler, AZ 85249, USA. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact. © 2002-2022 Sunvalley Communication, LLC